Moderna's business model is structured around the commercialization of its mRNA platform technology across three distinct revenue streams: approved vaccine products, government contract and grant funding for pipeline development, and strategic collaboration agreements with pharmaceutical partners that provide upfront and milestone payments in exchange for access to Moderna's platform for specific therapeutic areas. **The Platform-as-a-Business Model** The foundational logic of Moderna's business model is that mRNA is a platform technology — meaning the same core technological components (mRNA design, chemical modification, LNP delivery, manufacturing process) can be applied to a theoretically unlimited range of therapeutic targets by changing the genetic sequence encoded in the mRNA. This platform logic implies that Moderna's investment in core technology is amortized across an expanding pipeline of products, and that the marginal cost of developing a new candidate is significantly lower than the first candidate because the platform infrastructure already exists. This is a fundamentally different model from traditional pharmaceutical companies, which typically develop each drug through a bespoke discovery and development process with limited technology transfer across therapeutic areas. Moderna's model is closer to a semiconductor foundry or a software platform — the core technology is built once and then applied to multiple problems, with each application benefiting from the learning accumulated in previous applications. The commercial viability of this model depends on two conditions: that mRNA can be made to work for a sufficient number of therapeutic targets to justify the platform investment, and that Moderna can capture enough of the value created by those therapeutics to generate returns exceeding the cost of the platform. The COVID-19 vaccine provided extraordinary validation of the first condition and extraordinary financial returns from the second — but both conditions require sustained validation across the post-COVID pipeline. **Approved Products and Commercial Revenue** Moderna's commercial revenue comes primarily from its COVID-19 vaccine (Spikevax), its RSV vaccine (mRESVIA, approved by the FDA in May 2024), and government supply agreements for pandemic preparedness stockpiles. Spikevax revenue has declined sharply from its 2021–2022 peak as the COVID-19 vaccine market transitioned from mass vaccination to annual booster cycles with smaller addressable populations and increased competition from Pfizer-BioNTech's Comirnaty. The RSV vaccine approval in 2024 represents Moderna's second commercial product and the first non-COVID mRNA vaccine to reach market approval. mRESVIA targets adults 60 and older and competes with GSK's Arexvy and Pfizer's Abrysvo in the established RSV vaccine market. The commercial performance of mRESVIA is strategically significant beyond its direct revenue contribution — it validates that Moderna's mRNA platform can produce approved vaccines in therapeutic areas beyond COVID-19, demonstrating the platform's breadth and reducing investor concerns about single-product dependence. **Government Contracts and BARDA Funding** Moderna has maintained a substantial relationship with the U.S. Biomedical Advanced Research and Development Authority (BARDA) and equivalent government agencies internationally, receiving funding for pandemic preparedness vaccines, influenza vaccine development, and other public health priority programs. These contracts provide both funding for pipeline development and strategic alignment with government procurement priorities — important for a company whose largest commercial opportunity may continue to involve government-negotiated supply agreements. **Collaboration Revenue and Partnerships** Moderna has historically generated revenue from collaboration agreements with pharmaceutical partners — including AstraZeneca (for cardiovascular and oncology mRNA applications) and Blackstone (for mRNA manufacturing scale-up financing). These collaborations provide upfront payments, milestone payments tied to clinical and regulatory achievements, and in some cases royalties on commercial sales of products developed under the collaboration. The collaboration model serves two strategic purposes: it provides non-dilutive capital for pipeline development without requiring Moderna to wholly self-fund every program, and it validates the commercial interest of established pharmaceutical companies in Moderna's platform — a form of expert endorsement that supports investor confidence in the platform's long-term value.